Most users report that gains in body composition and metabolic markers hold partially during the off period, particularly if diet and training remain consistent
Setmelanotide (RM-493), Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl Syndrome (BBS) and Alstrm Syndrome (AS) Patients With Moderate to Severe Obesity
Total insulin degludec concentration (i.e., exposure) increased in a dose proportional manner after subcutaneous administration of 0.4 units/kg to 0.8 units/kg TRESIBA
"Ipamorelin, the first selective growth hormone secretagogue." European journal of endocrinology 139.5 (1998): 552-561
Complementary treatment in muscular .dystrophies and other myopathies, weakness and convalescence
thyroid cancer or hyperthyroidism, gastroparesis, pancreatic cancer or pancreatitis, MEN2 syndrome, or inflammatory bowel disease)